Monetising genetic data: how can blockchain help individuals?

In 2015, 23andMe, a California-based genetic company, reportedly sold its customers’ data to biotech company, Genentech, for $60 million. This collaboration aimed at developing a drug for Parkinson’s disease was initially chastised by authorities for operating without the US FDA’s clearance. Whilst the partnership was profitable to both companies, what …